{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000526","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.158009+00:00","generated_at":"2026-05-24T01:33:51.029369+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data","bullets":["FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.","LIBERATE-1 (NPM-115 exenatide) fully enrolled; top-line data expected mid-2025.","NPM-139 (semaglutide) preclinical data positive, once-yearly dosing potential.","Closed $8.25M equity financing on March 27, 2025 to fund into Q2 2026.","Plans to spin off Cortigent subsidiary as independent public company."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000526","json":"https://secwatch.observer/filing/0001753926-25-000526.json","markdown":"https://secwatch.observer/filing/0001753926-25-000526.md","text":"https://secwatch.observer/filing/0001753926-25-000526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000526/0001753926-25-000526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000526/vani-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:33:51.029369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}